IL18 and non-small cell lung carcinoma: Objective tumoral response was analyzed by <sup>18</sup>FDG PET-CT at baseline, 7 weeks, and 3 months post treatment induction, using PERCIST criteria.<h4>Results</h4>Plasmatic IL-18BP and total IL-18 levels are increased at baseline in NSCLC patients compared with healthy controls, whereas IL-18/IL-18BP complexes are decreased, and free IL-18 levels remain unchanged.